FDLI/FDA Conference In Brief

Food prioritized in FDA Globalization Act: The House Energy and Commerce Committee will break out food safety provisions from the FDA Globalization Act, H.R. 759, as a separate bill since Chairman Henry Waxman and others in Congress have made securing the food supply a top priority. Speaking at the Food and Drug Law Institute/FDA conference in Washington April 23, Energy and Commerce majority counsel Rachel Sher explained the committee is attempting to squeeze in work on food safety with other top legislative priorities, namely health care reform and carbon emission cap-and-trade. In addition to using FDAGA "as a foundation to draft a strong food safety bill," as Waxman, D-Calif., has suggested, Sher said the chairman "intends to look closely" at Rep. Rosa DeLauro's Food Safety Modernization Act, H.R. 875, in which the Connecticut Democrat proposes placing food safety in a new agency outside FDA. Sher said Waxman is seeking additional authorities for FDA, including access to manufacturer records and mandatory recall. While Waxman would prefer not to resort to user fees to fund the agency's food safety initiatives, "the need for a stronger food program is so dire that if it appears the monies we're able to come up with through the appropriations process are inadequate, he believes we must look to regulated industry to help," Sher said. The committee will address drug, device and cosmetic provisions of FDAGA after food safety, Sher added. Michigan Democrat John Dingell introduced FDAGA in January (1"The Tan Sheet" March 16, 2009, p. 16)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Brazil Could Look To Germany, UK And Australia For ATMP Drug Pricing Rules

 

There is a place for using external reference pricing to set prices of advanced therapies, but any such mechanism must take into account the specificities of the Brazilian market and health system.

Lerodalcibep And First Generic Palbociclib Among 10 New EMA Filings

 

Lerodalcibep and palbociclib are among the latest new drugs that the European Medicines Agency has started to review for potential EU marketing authorization.

Welireg Among Japan Recommendations; Economic Policy Raises Hopes Of Higher Prices

 
• By 

Country recommends eights new drugs for approval, including six for rare diseases, and also announces macroeconomic policy the pharma industry says would enable some reimbursement prices to be raised.